Literature DB >> 7472782

p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.

M D Jeffers1, M A Farquharson, J A Richmond, A M McNicol.   

Abstract

Mutation and overexpression of p53 have been described in uterine malignant mixed Müllerian tumours and in endometrial adenocarcinoma, where it has been associated with a poor prognosis. This study examines p53 expression and mutation of the p53 gene in benign and malignant smooth muscle tumours of the uterine corpus. p53 expression was evaluated by immunohistochemistry in formalin-fixed, paraffin-embedded tissue from 23 leiomyosarcomas, 10 tumours of uncertain malignant potential (TUMPs), and 18 leiomyomas. Single-stranded conformational polymorphism, (SSCP) analysis of exons 5-8 of the p53 gene was performed on 13 leiomyosarcomas, nine TUMPs, and eight leiomyomas. With microwave antigen retrieval, p53 immunoreactivity was seen in 13/23 microwave treatment, staining was abolished in three leiomyosarcomas, all immunoreactive TUMPs, and the single positive leiomyoma. SSCP analysis revealed mutation in three leiomyosarcomas. There was one mutation in exon 5 in a case with positive immunohistochemistry. Two cases with negative staining showed mutation, one in exon 7 and one in exon 8. Mutation was present in exon 7 in 4/9 and in exon 6 in 1/9 TUMPs. All of these cases showed positive immunohistochemistry. There was no significant difference in outcome between cases with and without positive immunohistochemistry. p53 expression is seen in a significant proportion of uterine leiomyosarcomas. Microwave antigen retrieval increases the proportion of positive cases and also results in positive staining in TUMPs. Mutation of the p53 gene occurs in only a minority of leiomyosarcomas and in a significant proportion of TUMPs. Positive immunohistochemistry does not, however, correlate with the presence of mutation and other factors may be responsible for p53 detection in many cases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7472782     DOI: 10.1002/path.1711770111

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  8 in total

1.  A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.

Authors:  Weiwei Shan; Patricia Y Akinfenwa; Kari B Savannah; Nonna Kolomeyevskaya; Rudolfo Laucirica; Dafydd G Thomas; Kunle Odunsi; Chad J Creighton; Dina C Lev; Matthew L Anderson
Journal:  Clin Cancer Res       Date:  2012-04-25       Impact factor: 12.531

2.  Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.

Authors:  Sabrina Croce; Agnes Ribeiro; Celine Brulard; Jean-Christophe Noel; Frederic Amant; Eberhard Stoeckle; Mojgan Devouassoux-Shisheborah; Anne Floquet; Laurent Arnould; Frederic Guyon; Florence Mishellany; Delphine Garbay; Tine Cuppens; Michal Zikan; Agnès Leroux; Eric Frouin; Pierre Duvillard; Philippe Terrier; Isabelle Farre; Isabelle Valo; Gaetan M MacGrogan; Frederic Chibon
Journal:  Mod Pathol       Date:  2015-05-01       Impact factor: 7.842

3.  The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.

Authors:  P Alhopuro; S K Ylisaukko-Oja; W J Koskinen; P Bono; J Arola; H J Järvinen; J-P Mecklin; T Atula; R Kontio; A A Mäkitie; S Suominen; I Leivo; P Vahteristo; L-M Aaltonen; L A Aaltonen
Journal:  J Med Genet       Date:  2005-09       Impact factor: 6.318

4.  A mouse model of uterine leiomyosarcoma.

Authors:  Katerina Politi; Matthias Szabolcs; Peter Fisher; Ana Kljuic; Thomas Ludwig; Argiris Efstratiadis
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

Review 5.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

6.  Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors.

Authors:  Iman H Hewedi; Nehal A Radwan; Lobna S Shash
Journal:  Diagn Pathol       Date:  2012-01-05       Impact factor: 2.644

7.  Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus.

Authors:  Y L Zhai; T Nikaido; T Toki; A Shiozawa; A Orii; S Fujii
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

8.  Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.

Authors:  Netta Mäkinen; Mervi Aavikko; Tuomas Heikkinen; Minna Taipale; Jussi Taipale; Riitta Koivisto-Korander; Ralf Bützow; Pia Vahteristo
Journal:  PLoS Genet       Date:  2016-02-18       Impact factor: 5.917

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.